Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience announced promising results from its HeROPA phase 2b trial for HRO350, a novel oral treatment for mild-to-moderate psoriasis, showing increased efficacy and a favorable safety profile over 52 weeks. The trial, conducted across five European countries, demonstrated that HRO350 achieved higher rates of ‘clear’ or ‘almost clear’ skin compared to placebo, with no new safety concerns, positioning the company for further development through partnerships or project funding.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company focused on developing and commercializing pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is advancing HRO350, a novel oral drug candidate aimed at treating mild-to-moderate psoriasis, and markets nutraceuticals globally under the ROMEGA® brand.
YTD Price Performance: 159.23%
Average Trading Volume: 1,875
Technical Sentiment Signal: Buy
Current Market Cap: €10.29M
Learn more about 9TD stock on TipRanks’ Stock Analysis page.